Trial Profile
RANDOMIZED PHASE II STUDY OF SORAFENIB PLUS GEMCITABINE OR SORAFENIB PLUS ERLOTINIB IN ADVANCED NON SMALL CELL LUNG CANCER (NSCLC) ELDERLY OR PS 2 PATIENTS.
Status:
Recruiting
Phase of Trial:
Phase II
Latest Information Update: 02 Apr 2012
Price :
$35
*
At a glance
- Drugs Sorafenib (Primary) ; Erlotinib; Gemcitabine
- Indications Non-small cell lung cancer
- Focus Therapeutic Use
- Acronyms GEST
- 22 Jul 2011 New trial record